Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
These updated results provide further evidence of sustained antitumor activity of T-DXd with a consistent safety profile in heavily pretreated patients with HER2-positive mBC.
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
Riverchase
无极微光
殷勤的紫槐
哈哈哈
小小
One
刚硬小阿博
欣慰猕猴桃
阿申爱乐
盒子
tiptip
带头大哥
贪玩的秋柔
cc2004bj
诚心的小x
嘉心糖
缓慢怜菡
Maestro_S
Criminology34
皖公网安备34019202002308
